Clinical Trials
1,249 trialsPED-DNX2401
Clinica Universidad de Navarra, Universidad de Navarra
NiloPost-STIM
University Hospital, Bordeaux
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
University of Pennsylvania
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sun Yat-sen University
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
Fudan University
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
GBM AGILE
Global Coalition for Adaptive Research
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University
STARLING
Indiana University
MRG003
Sun Yat-sen University
CrEATE
UMC Utrecht
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Peking University People's Hospital
SPiReL
Sunnybrook Health Sciences Centre
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Hoosier Cancer Research Network
ARISTOCRAT
University of Birmingham
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Shenzhen University General Hospital
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
EMBRACE
Ontario Clinical Oncology Group (OCOG)
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
M.D. Anderson Cancer Center
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
FUDOSE
UNICANCER
Vandevol
University Hospital, Lille
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Chronic Convection Enhanced Delivery of Topotecan
Columbia University
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
Study of Lacutamab in Peripheral T-cell Lymphoma
The Lymphoma Academic Research Organisation
GASTIVA
Samsung Medical Center
TROY
Yonsei University
AB154 Combined With AB122 for Recurrent Glioblastoma
Yale University
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Fondazione Italiana Linfomi - ETS
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Kousai Bio Co., Ltd.